Vero Biotech LLC, a biopharmaceutical company focused on the design, development and commercialisation of next generation inhaled nitric oxide (NO), announced on Friday that it has named Michael Gentile, MBA, RRT, FAARC, FCCM, as vice president of Medical Affairs.

Gentile joins Vero Biotech from Duke University School of Medicine and Health System in Durham, NC, and brings to the company more than 30 years of clinical practice, clinical research, teaching, and leadership. He has served in key positions for societies such as AARC, SCCM, ACCP, and ACHE.

In the new role, Gentile will be responsible for development of hospital education, clinical development, clinical operations, and data analysis and will contribute his expertise to solution development.